BT Group (BTGOF)
Bid | 2.36 |
Market Cap | 22.89B |
Revenue (ttm) | 20.36B |
Net Income (ttm) | 1.05B |
EPS (ttm) | 0.14 |
PE Ratio (ttm) | 16.79 |
Forward PE | 13.69 |
Analyst | n/a |
Dividends | $0.18 |
Ask | 2.55 |
Volume | 6,002 |
Avg. Volume (20D) | 20,325 |
Open | 2.35 |
Previous Close | 2.42 |
Day's Range | 2.35 - 2.35 |
52-Week Range | 1.60 - 2.97 |
Beta | 0.53 |
Ex-Dividend Date | Aug 8, 2025 |
About BTGOF
undefined

2 weeks ago · proactiveinvestors.co.uk
Physics jokes aside, BT is still a 'sell', says leading bankPhysics jokes are not standard fare in City research notes, but Deutsche Bank could not resist. Its analyst Robert Grindle has likened BT Group PLC's (LSE:BT.A) new chief executive to a “quantum-confi...

2 weeks ago · businesswire.com
BT and Infobip Expand Partnership to Deliver AI-Powered CommunicationsVODNJAN, Croatia--(BUSINESS WIRE)--BT and Infobip have announced the global expansion of their partnership to deliver AI-powered advanced communication services to multinational businesses worldwide. ...

3 weeks ago · proactiveinvestors.co.uk
BT remains on the 'sell' list of two major investment banksAnalyst coverage of BT Group PLC (LSE:BT.A) had a negative hue to it on Thursday, with both Citi and Deutsche Bank reiterating 'sell' recommendations. The American bank, with a 140p target price, caut...

2 months ago · accessnewswire.com
Transgene and BioInvent to Present Updated Data on Armed Oncolytic virus BT-001 at ESMO 2025- Poster presentation of updated data on BT-001 from the Phase 1 part of the ongoing Phase 1/2a study in solid tumors - LUND, SE / ACCESS Newswire / July 28, 2025 / BioInvent International AB ("BioInv...